logo
'Being spiked on a night out traumatised me'

'Being spiked on a night out traumatised me'

Yahoo11-05-2025

A 19-year-old woman who believes she was spiked says she was "miserably failed" by hospital staff and says a nurse dismissed her as drunk.
Libby Wolford, from Porth, Rhondda Cynon Taff, was on a night out with friends on 25 April when she experienced the "scary" incident that left her "traumatised", "screaming in pain", and unable to walk or talk.
After briefly leaving her drink unattended to use the toilet, Ms Wolford returned and took a sip and within moments, she went from "nought to 100 in seconds".
A Welsh government advisor has called for stronger laws, better training, and more support for victims of spiking to ensure they are taken seriously and offenders are held to account.
Ms Wolford had just finished her second drink at The Banc club in Pentre, Rhondda, when she suddenly began to feel "very unwell".
She spent about 15 minutes vomiting a green substance in the toilet and became disoriented, unable to understand those around her.
Her condition rapidly worsened, with severe stomach pain, dizziness, uncontrollable shaking, and breathing difficulties, which prompted her boyfriend to call her mother for help and to take her to A&E.
Ms Wolford said: "It got to a point where I was laying down in the back seat, and I was screaming in pain.
"I was just in so much agony.
"This is when I began to feel my airway starting to close because I couldn't breathe properly, and I was gasping for air.
"I was so out of it I just didn't know where I was or who I was."
Spiking to be made specific offence in King's Speech
Intervene if women at spiking risk, says minister
Man posed as woman's boyfriend after she was spiked
After arriving at the A&E department at the Royal Glamorgan Hospital in Ynysmaerdy, Rhondda Cynon Taf, Ms Wolford said a nurse dismissed her condition as being "just paralytic" and claimed she "sees it all the time" - despite Ms Wolford being unable to walk, talk, or understand what was happening.
After waiting for five hours, Ms Wolford made the decision to leave the hospital.
"It just got to the point where I got so fed up of waiting, and just not being able to get comfy," she said.
"I got really agitated, and I just wanted to go home."
Ms Wolford said the whole experience had shaken her up, left her constantly feeling unwell and "worrying wherever I go".
"It started as an amazing night, but after everything that happened, it turned into the worst night I've had in my 19 years.
"It's just such a scary world."
She said she had "absolutely no help" from the hospital and feels "miserably failed" as she was made to "feel so below other people".
While she acknowledges the NHS is under pressure and often deals with many drunk patients on weekends, she believes her symptoms were dismissed too quickly.
She added: "One day, it could happen to someone else, and they might have it 10 times worse.
"If my immune system hadn't been so strong, it could have ended a lot worse.
"Not every girl's body can handle or break down a drug like mine did, and it really angers me that nothing was done that day."
A spokesperson for Cwm Taf Morgannwg University Health Board said it cannot comment on individual cases but encouraged the patient to contact its concerns team directly.
In a statement, The Banc said it acted immediately after becoming aware of Ms Wolford's social media post.
The club emphasised that the safety of its customers and staff is its "top priority," and that free anti-spiking drink covers are now available upon request.
Ms Wolford said she wanted to share her story to "reduce the chances of this happening to anyone else ever again".
She urged women to be highly cautious with their drinks on nights out and hopes more clubs will adopt anti-spike lids to protect drinks.
In the UK, spiking is prosecuted under existing laws such as the Offences Against the Person Act and the Sexual Offences Act, with penalties of up to 10 years in prison.
However, in the King's Speech in July, it was announced a new specific offence for spiking would be introduced to improve clarity, support victims, and strengthen police responses.
In November, safeguarding minister Jess Phillips said bystanders should be prepared to step in and help women who appear at risk of spiking during the Christmas party season.
She also said up to 10,000 bar staff across the country would be trained to prevent spiking incidents, support victims and help police collect evidence.
St John Ambulance Cymru's clinical director Carl Lane, who is also an advanced paramedic, said spiking is "deeply dangerous and should always be taken seriously".
Signs include confusion, loss of coordination, slurred speech, or unconsciousness - never leave someone alone if they show these symptoms.
Seek urgent medical help; call 999 if someone is seriously unwell or unconscious, and use the recovery position or CPR if needed.
For less urgent cases, contact NHS 111 and always report suspected spiking to police.
Ms Wolford decided not to file a police report, fearing that "nothing would be done", and said she knew "lots of women who had reported spiking crimes" without seeing any action taken.
Corrie David from South Wales Police said the force takes all spiking reports seriously and urge anyone affected to come forward so investigations can take place.
He said police can conduct a rapid drugs test, and alert licensed premises to known spiking methods and offer training to staff in recognising signs of vulnerability.
Yasmin Khan, who advises the Welsh government on violence against women and sexual violence, said spiking is a misunderstood and under-reported crime, largely due to the "limited forensic window" and victims feeling shame or "completely hopeless".
She said reports of drink and needle spiking have increased.
"It's such an abuse of power and it's just unbelievable," Ms Khan said.
"The impact spiking has on victims is lifelong."
She called for better training in healthcare and hospitality, more support for victims, and a stronger focus on listening to survivors.
"We really have got to hold perpetrators to account," she said.
Stephanie Grimshaw, from Welsh Women's Aid said sexual assault referral centres such as New Pathways in Wales provide specialist support and evidence gathering for survivors.
She said "disappointing" victim-blaming attitudes in healthcare made it hard for women to feel safe and believed, and stressed that supportive responses and proper training were essential to "help survivors feel confident in coming forward".
Catcalls and being followed: Why I'm scared to run
The women killed by men in Wales since 2020
Clubs say they work hard to prevent spiking

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults

Business Upturn

time5 hours ago

  • Business Upturn

BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults

Denver, June 06, 2025 (GLOBE NEWSWIRE) — BrainDefender Research today announced the launch of BrainDefender Memory Support Supplement , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. Availability BrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender Research BrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: [email protected] Phone: (855) 473-4405 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults

Yahoo

time8 hours ago

  • Yahoo

BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults

Plant-Based Supplement Includes Five Individual Ingredients Studied for Their Role in Supporting Memory and Focus Denver, June 06, 2025 (GLOBE NEWSWIRE) -- BrainDefender Research today announced the launch of , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. AvailabilityBrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender ResearchBrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. DisclaimerThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: support@ Phone: (855) 473-4405 CONTACT: Email: support@ Phone: (855) 473-4405Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

Business Wire

time19 hours ago

  • Business Wire

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review. OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025. The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications. In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store